Activity of any class IA PI3K isoform can sustain cell proliferation and survival

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 25, 2010, Pages 11381-11386

  Foukas, Lazaros C ^a,d   Berenjeno, Inma M ^a   Gray, Alexander ^b   Khwaja, Asim ^c   Vanhaesebroeck, Bart ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Cancer therapeutics; Combination therapy; Inhibitors; MAP kinase

Indexed keywords

INTERLEUKIN 3; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE P110ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE P110BETA; PHOSPHATIDYLINOSITOL 3 KINASE P110DELTA; PHOSPHATIDYLINOSITOL 3 KINASE P110GAMMA; UNCLASSIFIED DRUG; 1 PHOSPHATIDYLINOSITOL 3 KINASE P110 SUBUNIT, MOUSE; 1-PHOSPHATIDYLINOSITOL 3-KINASE P110 SUBUNIT, MOUSE; ENZYME INHIBITOR; ISOPROTEIN; PIK3CD PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; FIBROBLAST; GENE INACTIVATION; HEMATOPOIETIC STEM CELL; LEUKOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; CHEMISTRY; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; MUTATION; NEOPLASM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CELL PROLIFERATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LEUKOCYTES; MAP KINASE SIGNALING SYSTEM; MICE; MUTATION; NEOPLASMS; PROTEIN ISOFORMS;

EID: 77954903710     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0906461107     Document Type: Article

References (48)

1. Kok K, Geering B, Vanhaesebroeck B (2009) Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 34:115-127.
2. Shayesteh L, et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99-102. (Pubitemid 29036292)
3. Samuels Y, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554. (Pubitemid 38541907)
4. Vogt PK, Kang S, Elsliger MA, Gymnopoulos M (2007) Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32:342-349.
5. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27:5497-5510.
6. Guillermet-Guibert J, et al. (2008) The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ. Proc Natl Acad Sci USA 105:8292-8297. (Pubitemid 351904749)
7. Kang S, Denley A, Vanhaesebroeck B, Vogt PK (2006) Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3- kinase. Proc Natl Acad Sci USA 103:1289-1294.
8. Foukas LC, et al. (2006) Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441:366-370. (Pubitemid 44050203)
9. Graupera M, et al. (2008) Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453:662-666.
10. Okkenhaug K, et al. (2002) Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 297:1031-1034.
11. Jackson SP, et al. (2005) PI 3-kinase p110beta: A new target for antithrombotic therapy. Nat Med 11:507-514. (Pubitemid 40685973)
12. Pomel V, et al. (2006) Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem 49:3857-3871. (Pubitemid 43967883)
13. Arcaro A, et al. (2002) Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J 21:5097-5108.
14. Sawyer C, et al. (2003) Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res 63:1667-1675. (Pubitemid 36373660)
15. Boller D, et al. (2008) Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 14:1172-1181. (Pubitemid 351302566)
16. Dzierzak E, Speck NA (2008) Of lineage and legacy: The development of mammalian hematopoietic stem cells. Nat Immunol 9:129-136.
17. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC (2005) Signalling by PI3K isoforms: Insights from gene-targeted mice. Trends Biochem Sci 30:194-204. (Pubitemid 40463309)
18. Yu W-M, Hawley TS, Hawley RG, Qu C-K (2002) Immortalization of yolk sac-derived precursor cells. Blood 100:3828-3831.
19. Hawley RG, et al. (1997) Transforming function of the HOX11/TCL3 homeobox gene. Cancer Res 57:337-345.
20. Vanhaesebroeck B, et al. (1997) P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 94:4330-4335. (Pubitemid 27194241)
21. Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B (2007) Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci USA 104:7809-7814. (Pubitemid 47185833)
22. Gold MR, Duronio V, Saxena SP, Schrader JW, Aebersold R (1994) Multiple cytokines activate phosphatidylinositol 3-kinase in hemopoietic cells. Association of the enzyme with various tyrosine-phosphorylated proteins. J Biol Chem 269:5403-5412. (Pubitemid 24239539)
23. GrayA, Olsson H, Batty IH, Priganica L, PeterDownes C (2003)Nonradioactivemethods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal Biochem 313:234-245. (Pubitemid 36259947)
24. Gu H, et al. (2000) New role for Shc in activation of the phosphatidylinositol 3-kinase/ Akt pathway. Mol Cell Biol 20:7109-7120.
25. O'Gorman DM, McKenna SL, McGahon AJ, Knox KA, Cotter TG (2000) Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3- kinase survival signals. Leukemia 14:602-611.
26. Zhao Y, et al. (2004) Distinctive regulation and function of PI 3K/Akt and MAPKs in doxorubicin-induced apoptosis of human lung adenocarcinoma cells. J Cell Biochem 91:621-632.
27. Wang YA, et al. (2008) Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Int J Cancer 123:1536-1544.
28. Goodarzi AA, Lees-Miller SP (2004) Biochemical characterization of the ataxiatelangiectasia mutated (ATM) protein from human cells. DNA Repair (Amst) 3:753-767.
29. Hall-Jackson CA, Cross DA, Morrice N, Smythe C (1999) ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK. Oncogene 18:6707-6713.
30. Izzard RA, Jackson SP, Smith GC (1999) Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res 59:2581-2586. (Pubitemid 29269102)
31. Jia S, Roberts TM, Zhao JJ (2009) Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 21:199-208.
32. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL (1999) Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J Biol Chem 274:10963-10968. (Pubitemid 129528301)
33. Zhao JJ, et al. (2006) The p110alpha isoformof PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci USA 103:16296-16300.
34. Jia S, et al. (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454:776-779.
35. Ciraolo E, et al. (2008) Phosphoinositide 3-kinase p110beta activity: Key role in metabolism and mammary gland cancer but not development. Sci Signal 1:ra3.
36. Marqués M, et al. (2008) Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol 28: 2803-2814. (Pubitemid 351542377)
37. Zhu Q, et al. (2008) Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 27:4569-4579.
38. Torbett NE, et al. (2008) A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J 415:97-110.
39. Wee S, et al. (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 105:13057-13062.
40. Raynaud FI, et al. (2007) Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67:5840-5850.
41. Dan S, Yoshimi H, Okamura M, Mukai Y, Yamori T (2009) Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. Biochem Biophys Res Commun 379:104-109.
42. Fan QW, et al. (2007) A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67:7960-7965.
43. Papakonstanti EA, et al. (2008) Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J Cell Sci 121:4124-4133.
44. Gupta S, et al. (2007) Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129:957-968. (Pubitemid 46802703)
45. Engelman JA, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356.
46. Guillard S, et al. (2009) Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle 8:443-453.
47. Degtyarev M, et al. (2008) Akt inhibition promotes autophagy and sensitizes PTENnull tumors to lysosomotropic agents. J Cell Biol 183:101-116.
48. Lum JJ, et al. (2005) Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120:237-248. (Pubitemid 40174766)